Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-05, Vol.30, p.iii50-iii50 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | iii50 |
|---|---|
| container_issue | |
| container_start_page | iii50 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Welt, A. Welslau, M.K. Lüftner, D. Deryal, M. Liersch, R. Sahlmann, J. Houet, L. Vannier, C. Marschner, N. Potthoff, K. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz100.007 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdz100_007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419304247</els_id><sourcerecordid>32084840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1607-7fb8dc6ab9b21156a28893c1eb598b949534d34ccd7a42592c45933a55a406123</originalsourceid><addsrcrecordid>eNp9kc-O0zAQxi0EYrsLD8AFzR2ytZ2_hhOsSltpBWgF52jsOKqR40S201V4Oh4NVwGOnEYz-n4zo-8j5BWjt4yKfIvOjU5th-4no_SW0voJ2bCyEllDC_aUbKjgeVaXeXFFrkP4QSmtBBfPyVXOaVM0Bd2QX1_RylEZZY2Eyc4B-tmedYgeXQRMrfEhZtY4DfGkPU4L9KOHCaPRLgZ4NPEEdlRo7QLYndEp3b0F48YpqaXVkNSDjhhiQhQcHt5sD7sHnoH0Og1BXQifANhrP6Bb3sHRRe3NAF6H2aYbY3-5DcfP-132EaYThtQcIcS5W16QZz3aoF_-qTfk-6fdt7tDdv9lf7z7cJ8pVtE6q3vZdKpCKSRnySPkTSNyxbQsRSNFIZJLXV4o1dVY8FJwVZQiz7EssaAV4_kNYete5ccQvO7bKb2IfmkZbS9ptGsa7ZpGm9JIzOuVmWY56O4f8df-JHi_CnT6_Gy0b4NKtiYHjdcqtt1o_rP-Nzuxny8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Welt, A. ; Welslau, M.K. ; Lüftner, D. ; Deryal, M. ; Liersch, R. ; Sahlmann, J. ; Houet, L. ; Vannier, C. ; Marschner, N. ; Potthoff, K.</creator><creatorcontrib>Welt, A. ; Welslau, M.K. ; Lüftner, D. ; Deryal, M. ; Liersch, R. ; Sahlmann, J. ; Houet, L. ; Vannier, C. ; Marschner, N. ; Potthoff, K.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz100.007</identifier><identifier>PMID: 32084840</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2019-05, Vol.30, p.iii50-iii50</ispartof><rights>2019 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32084840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Welt, A.</creatorcontrib><creatorcontrib>Welslau, M.K.</creatorcontrib><creatorcontrib>Lüftner, D.</creatorcontrib><creatorcontrib>Deryal, M.</creatorcontrib><creatorcontrib>Liersch, R.</creatorcontrib><creatorcontrib>Sahlmann, J.</creatorcontrib><creatorcontrib>Houet, L.</creatorcontrib><creatorcontrib>Vannier, C.</creatorcontrib><creatorcontrib>Marschner, N.</creatorcontrib><creatorcontrib>Potthoff, K.</creatorcontrib><title>Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc-O0zAQxi0EYrsLD8AFzR2ytZ2_hhOsSltpBWgF52jsOKqR40S201V4Oh4NVwGOnEYz-n4zo-8j5BWjt4yKfIvOjU5th-4no_SW0voJ2bCyEllDC_aUbKjgeVaXeXFFrkP4QSmtBBfPyVXOaVM0Bd2QX1_RylEZZY2Eyc4B-tmedYgeXQRMrfEhZtY4DfGkPU4L9KOHCaPRLgZ4NPEEdlRo7QLYndEp3b0F48YpqaXVkNSDjhhiQhQcHt5sD7sHnoH0Og1BXQifANhrP6Bb3sHRRe3NAF6H2aYbY3-5DcfP-132EaYThtQcIcS5W16QZz3aoF_-qTfk-6fdt7tDdv9lf7z7cJ8pVtE6q3vZdKpCKSRnySPkTSNyxbQsRSNFIZJLXV4o1dVY8FJwVZQiz7EssaAV4_kNYete5ccQvO7bKb2IfmkZbS9ptGsa7ZpGm9JIzOuVmWY56O4f8df-JHi_CnT6_Gy0b4NKtiYHjdcqtt1o_rP-Nzuxny8</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Welt, A.</creator><creator>Welslau, M.K.</creator><creator>Lüftner, D.</creator><creator>Deryal, M.</creator><creator>Liersch, R.</creator><creator>Sahlmann, J.</creator><creator>Houet, L.</creator><creator>Vannier, C.</creator><creator>Marschner, N.</creator><creator>Potthoff, K.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201905</creationdate><title>Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study</title><author>Welt, A. ; Welslau, M.K. ; Lüftner, D. ; Deryal, M. ; Liersch, R. ; Sahlmann, J. ; Houet, L. ; Vannier, C. ; Marschner, N. ; Potthoff, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1607-7fb8dc6ab9b21156a28893c1eb598b949534d34ccd7a42592c45933a55a406123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Welt, A.</creatorcontrib><creatorcontrib>Welslau, M.K.</creatorcontrib><creatorcontrib>Lüftner, D.</creatorcontrib><creatorcontrib>Deryal, M.</creatorcontrib><creatorcontrib>Liersch, R.</creatorcontrib><creatorcontrib>Sahlmann, J.</creatorcontrib><creatorcontrib>Houet, L.</creatorcontrib><creatorcontrib>Vannier, C.</creatorcontrib><creatorcontrib>Marschner, N.</creatorcontrib><creatorcontrib>Potthoff, K.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Welt, A.</au><au>Welslau, M.K.</au><au>Lüftner, D.</au><au>Deryal, M.</au><au>Liersch, R.</au><au>Sahlmann, J.</au><au>Houet, L.</au><au>Vannier, C.</au><au>Marschner, N.</au><au>Potthoff, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2019-05</date><risdate>2019</risdate><volume>30</volume><spage>iii50</spage><epage>iii50</epage><pages>iii50-iii50</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32084840</pmid><doi>10.1093/annonc/mdz100.007</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-05, Vol.30, p.iii50-iii50 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdz100_007 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A28%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Palbociclib%20plus%20fulvestrant%20as%20first-line%20therapy%20for%20patients%20with%20locally%20advanced,%20inoperable%20or%20metastatic%20HR+/HER2-%20breast%20cancer%20in%20Germany:%20Interim%20results%20of%20the%20INGE-B%20phase%20II%20study&rft.jtitle=Annals%20of%20oncology&rft.au=Welt,%20A.&rft.date=2019-05&rft.volume=30&rft.spage=iii50&rft.epage=iii50&rft.pages=iii50-iii50&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz100.007&rft_dat=%3Cpubmed_cross%3E32084840%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32084840&rft_els_id=S0923753419304247&rfr_iscdi=true |